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EDITORIAL
PEPTIC ULCER DISEASE AND ITS COMPLICATIONS
 
Peptic ulceration commonly involves the 
stomach, duodenum and lower oesophagus, 
and after gastric surgery, the gastro-enterostomy 
stoma. Collectively these afﬂictions go under the 
term peptic ulcer disease (PUD). This condition 
is common in East Africa, according to reports 
from Eldoret (1) and Nairobi (2) and a major 
cause of morbidity and mortality. Although the 
pathophysiology is still not fully understood we 
know that bacterial, host, environmental and 
pharmacological factors play a role in varying 
proportions in the causation and propagation 
of this disease and these can be classiﬁed as 
aggressive when they promote ulcer formation or 
defensive if they protect gastro-duodenal mucosa 
and advance healing (3). Aggressive factors which 
predispose to gastric and duodenal ulceration 
act by causing breakdown of the barrier that 
normally prevents irritation and autodigestion 
of the mucosa by the gastric secretions. Three of 
these are gastric acid, infection with Helicobacter 
pylori and use of non-steroidal anti-inﬂammatory 
drugs (NSAIDs). Gastric acid is produced by the 
parietal (oxyntic) cells in the glands of the body 
and fundus of the stomach, which also produce 
the intrinsic factor. These glands also contain chief 
(zymogen, peptic) cells which secrete pepsinogens. 
Infection with the bacterium H. pylori disrupts 
the protective barrier and predisposes to PUD 
while aspirin and other NSAIDs promote PUD by 
inhibiting the production of prostaglandins and a 
decrease in mucus and HCO3 secretion. NSAIDs 
are widely used to combat pain in a variety of 
clinical settings. 
Several mechanisms are important in 
the protection of the mucosa from ulceration, 
and they are either natural or pharmacological 
(4). The former include mucus, bicarbonate, 
prostaglandins, depth of the gastric pits and trefoil 
peptides, and together form the mucosal barrier. 
Mucus consists of a glycoprotein containing 
mucins which form a ﬂexible gel coating the 
mucosa and is produced by glands in the pyloric 
and cardiac regions of the stomach which also 
produce bicarbonate. Prostaglandins stimulate 
mucus and HCO3 secretion. The deep gastric pits 
play a protective role since hydrochloric acid 
with a pH of 1 produced deep in these pits is 
neutralised by mucus and HCO3 before reaching 
the surface. There are also trefoil peptides in 
the mucosa which are protective. Drugs play a 
protective role by inhibition of gastric secretion, 
with the main ones in current use being H2 
histamine receptor antagonists, proton pump 
inhibitors, antibiotics against H. pylori, and 
misoprostol which is discussed below. 
Because of our better understanding of 
the above, management of PUD has changed 
considerably and today PUD sufferers can look 
forward to better treatment and outcomes than 
did their counterparts of half a century ago. It is 
pertinent to review some of the factors which have 
changed our view of this disease. Long before 
current therapy was established the incidence of 
PU and admissions for uncomplicated DU had 
been dropping in the USA (3). This was due to 
better general health, protection of the stomach 
and duodenal mucosa through better eating habits, 
diet and campaign against ulcerogenic habits 
such as taking of alcohol and caffeine, reduced 
smoking and use of antacids. An even more 
important contributor to change of management 
of PUD was progress in the pharmaceutical 
research which led to introduction of newer 
and more effective remedies, aimed at reducing 
gastric acid secretion, which has long been 
known to be a major contributor to PUD. Three 
groups of these drugs are worth of mention. First 
was introduction of H2-receptor antagonists like 
ranitidine and cimetidine which reduce gastric 
acid secretion as a result of histamine H2 receptor 
blockade. Ranitidine was shown to give superior 
results over previous therapy in the treatment of 
peptic ulceration in Kenyans (5) and is still widely 
used. This was followed by the protein pump 
inhibitors such as omeprazole and esomeprazole 
which decrease gastric acid output by blocking 
ATP dependent hydrogen-potassium system, 
also known as the proton pump of the gastric 
parietal cell (6). Use of highly selective inhibitors 
of cyclo-oxygenase-2 such as celecoxib (Celebrex) 
in place of the more ulcerogenic non steroidal 
anti-inﬂammatory drugs was yet another 
pharmacological step in the reduction of peptic 
ulcer disease since they have been shown to have 
a lower risk of serious upper gastrointestinal 
events. However their use has been somewhat 
limited by concerns about their cardiovascular 
safety and are contraindicated in ischaemic heart 
disease, cerebro-vascular disease, peripheral 
arterial disease and heart failure (7). 
The real revolution in the understanding 
and management of PUD occurred 25 years 
ago when Marshall and Warren (who spent an 
agonising period trying to prove their discovery 
to sceptical and unconvinced medical colleagues) 
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showed the link between the bacteria H. pylori 
and PUD (8). Their work profoundly changed our 
knowledge of and approach to PUD, introducing 
antibiotic therapy to the management of the 
disease and drastically reducing complications 
(9). In Kenya, Ogutu et al (10) showed the 
association between PUD and H. Pylori. Early in 
the 1980s upper GI endoscopy was introduced 
in Kenya and it proved safe and more accurate 
than both clinical examination and barium 
meal for diagnosing of diseases of the upper 
GIT (11,12). Duodenal ulcer was conﬁrmed by 
endoscopy as the commonest lesion in patients 
presenting with dyspepsia in Nairobi (2). Where 
this facility is available, patients get diagnosed 
earlier and treatment saves them from potentially 
complicated PUD. 
These positive developments have 
been countered to some extent by factors that 
tend to worsen PUD, the so called aggressive 
factors. First is the widespread use of NSAIDs 
in treating musculoskeletal conditions and 
their excessive use as analgesics, second is 
the increased use of aspirin in prevention of 
cardiovascular complications, and third is that 
people live longer, and in advanced age use more 
NSAIDs. NSAIDs relieve pain and inﬂammation 
by inhibition of prostaglandin synthesis whose 
side effect is weakening of the gastric mucosal 
defence to resist luminal irritants. Nitric oxide 
(NO) counters this and plays a protective role. 
While neutrophil adherence to the endothelium 
of the gastric capillaries may be critical in 
NSAID injury, NSAIDs may also induce activity 
of inﬂammatory mediators, tumour necrosis 
factor TNFa and leucotrienes. NSAID- induced 
ulcers can be treated by stopping the NSAIDs 
or when this is not advisable, by treatment 
with the prostaglandin agonist misoprostol. 
Misoprostol, a synthetic prostaglandin analogue 
has antisecretory and protective properties, 
promoting healing of gastric and duodenal ulcers. 
It can prevent NSAID- associated ulcers its use 
being most appropriate for the frail or elderly 
from whom NSAIDs cannot be withdrawn. 
It is sometimes combined with NSAIDs like 
diclofenac or naproxen (7). 
Due to these factors PU has increased 
in the older generation in the developed 
countries but is uncommon in the young. Not 
so in Africa. In this issue, Dakubo et al (13) 
writing from Ghana in West Africa found that 
most of their patients were young, conﬁrming 
a similar earlier ﬁnding in West Africa (14) 
and East Africa where patients with perforated 
duodenal ulcer were on average 20 years 
younger than those reported from America 
(15,16). This indicates that there are factors 
other than age which predispose to PUD and 
low socio-economic status seems to be one such 
factor. Apart from poverty and malnutrition, 
African patients report to hospitals late often 
with the disease advanced or complicated, and 
in any case most of the health facilities they 
attend are poorly equipped and understaffed. 
In addition there is widespread use and abuse 
of NSAIDs, sometimes self prescribed. The 
result of all this is that PUD is common and 
where PUD is high, so will the complications. 
The three classical surgical complications of 
PUD are haemorrhage, perforation and pyloric 
stenosis. 
Carswell and Zarezaev (17) reviewed 
these complications in a series from Kampala 
which is typical of many African countries. 
Gastric outlet obstruction was the commonest, 
but this was because it was the least serious of 
the three complications, since it took some time, 
often months to develop, and allowed patients to 
present themselves to the hospital. Moreover its 
diagnosis, in well established form, was difﬁcult 
to miss (18). Haemorrhage had a high chance of 
under-treatment due to deprived health facilities 
and there were many preventable deaths. The 
current accepted treatment for haemorrhage 
is upper GI endoscopy with injection with 
vasoconstrictors after resuscitation. Endoscopic 
facilities are not widely available and in many 
places on the continent and open surgery is still 
recommended. Post surgery, medical treatment 
with PPls is advised as recurrence is not 
uncommon (19). 
Perforation remains a major problem 
because of widespread use of NSAIDs and high 
prevalence of PUD particularly in rural areas. 
Very few cases were seen by Carswell and 
Zarezaev (17), but they were convinced most of 
the patients were dying untreated. 
Perforated peptic ulcer is often missed, 
and patients will succumb either acutely or due 
to subsequent complications. In Kampala even 
those correctly diagnosed and treated, had a high 
mortality. The standard treatment for perforation 
is laparotomy and closure by an omental patch. 
Few surgeons will advocate vagotomy or some 
other anti-ulcerogenic treatment after this, 
particularly now that there are effective drugs 
to treat those with residual PUD symptoms after 
surgery. Closure of perforated DU is an operation 
that lends itself very well to laparoscopy which, 
in experienced hands, is quicker, less traumatic 
and relatively easy to do and will in time replace 
open surgery. It is already practised in Kenya. 
The paper from West Africa (13) 
highlights the fact that this problem is still 
common, affecting mainly the young and has 
serious complications often leading to death. 
Clinicians must pay special attention to a disease 
that need not be such a great public health issue 
as it is at the moment. 
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